Digital Breast Tomosynthesis Equipment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Digital Breast Tomosynthesis Equipment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The digital breast tomosynthesis equipment market is expected to register a CAGR of 13.5% over the forecast period.

COVID-19 has affected the world and has had a major impact on the healthcare system. This outbreak has severy impacted the digital breast tomosynthesis equipment market. The pandemic resulted in substantial reductions in breast cancer screening, cancer management visits, and cancer procedures across the globe. For instance, in June 2022 a study published in the Journal of the American College of Radiology, titled "Mammography screening and related breast care still rebounding from COVID-19 pandemic" states that cancer diagnoses dropped by nearly 50% in the peak-pandemic period and have not rebounded completely to the pre-COVID rate. The strict lockdown and the policies led to the relocation of medical healthcare providers and material resources, which led the healthcare providers to focus primarily on this abrupt emergency, thereby postponing the other non-emergency medical services. Thus, elective and non-emergency medical procedures have nearly all halted in most medical centers. However, within a few months, the market showed significant growth due to the growing demand for these procedures.

The factors are that the market is the increasing prevalence of breast cancer worldwide, technological advancements in the field of breast imaging, and rising awareness about the use of digital breast tomosynthesis (DBT). The rising prevalence of breast cancer cases is increasing the number of screening mammography, thereby fueling the studied market. For instance, in 2020 International Agency for the research on Cancer reported that globally 2.26 million breast cancer cases were recorded in 2020, and this number is expected to increase to 3.19 million by the end of 2040. Thus, the increasing number of cancer cases is driving the digital breast tomosynthesis equipment market.

Also, technological advancements are fueling the growth of this segment. For instance, in August 2021, FUJIFILM Medical Systems launched its ASPIRE Cristalle mammography system with digital breast tomosynthesis (DBT) that offers ScreenPoint Medical’s new, United States Food and Drug Administration (USFDA) cleared Transpara powered by Fusion artificial intelligence (AI) for 2D and 3D mammography in the United States. Thus, such kind of advancements is making an early possible diagnosis of breast cancer, thereby fueling the market. Many organizations are working towards spreading awareness about breast cancer drugs globally. For instance, in October 2021, the Pink Bot breast cancer awareness campaign was initiated. The Pink Bot, a chat module integrated to answer queries on breast cancer is the latest initiative from Dr. P Guhan and his team to raise awareness of it. Similarly, in May 2022, Mount Sinai Health System initiated Mammogram May to empower women to take charge of their breast health by scheduling an annual mammogram. The goals of the campaign are to raise awareness of the importance of mammography in early breast cancer detection and treatment and to address a decline in breast screenings worsened by the pandemic.

Thus, due to the aforesaid mentioned reasons, the market is expected to show significant growth over a forecast period. However, the high costs of the systems and side effects associated with radiation exposure may slow down its growth over the forecast period.

Key Market Trends2D/3D Combination Mammography Systems Segment is Expected to Witness a Significant Growth Over the Forecast Period

2D/3D combination mammography systems segment may drive the market as 3D mammography combined with 2D mammography or synthetic 2D mammography can detect more cases of breast cancer as compared to 2D mammography alone. 2D/3D mammography systems require less follow-up imaging, detect more cancers than standard mammography alone, and improve breast cancer detection in dense breast tissues. The high detection rate, rising awareness among people about 2D/3D combination mammography systems, and increasing prevalence of breast cancer are the key factors driving this segment. For instance, in April 2022, an article published in the Journal of Oncology and Radiology titled, "Two-dimensional or three-dimensional imaging for breast cancer screening? An evaluation study of sensitivity and specificity from Northern Kerala, India" reported that 2D-3D mammograms had better sensitivity for non-palpable malignancies than 2D mammograms alone.

An article published in the Egyptian Journal of Radiology and Nuclear Medicine in January 2022 titled, “Performance evaluation of digital mammography, digital breast tomosynthesis, and ultrasound in the detection of breast cancer using pathology as the gold standard: an institutional experience” reported that the combination of digital breast tomosynthesis (DBT) to digital mammography(DM) led to higher diagnostic accuracy, sensitivity, and positive predictive value (PPV) and a total of 313 masses were picked up on 2D mammography alone while 2D and 3D mammography combined picked up 361 lesions thus showing that combination of 2D/3D mammography improves lesion visualization. Also, in 2021, World Health Organization (WHO), reported that in 2021 breast cancer is the most frequent type of cancer among women globally, approximately 2.1 million women suffer from breast cancer every year and the highest number of cancer-related deaths among women.

Thus, rising cases of breast cancer along with technological advancement, research & developments in this segment are driving the growth of the studied market, thereby expected to witness significant growth over the forecast period.

North America is Expected to Witness a Significant Growth Over the Forecast Period.

North America is expected to hold a major market share in the global digital breast tomosynthesis (DBT) equipment market due to the high demand for innovative products, and increasing adoption of screening methods. The growing prevalence of breast cancer, significant R&D in breast cancer therapies, and advancements in breast imaging modalities are the primary drivers of the market in this region. For instance, in 2020 International Agency for Research on Cancer, reported that in the year 2020 about 2.54 million breast cancer cases were reported in the region and this number is expected to increase to 3.53 million by 2040. Similarly, in January 2022, the American Cancer Society reported that breast cancer is the most common cancer in women in the United States, with about 1 in every 3 women being diagnosed with breast cancer. American Cancer Society has also estimated about 2,87,850 new cases of invasive breast cancer to be reported in women in the United States in 2022. Thus, the high incidence of breast cancer cases is driving the market in the region.

Furthermore, technological advancements, research and development, mergers, partnerships, acquisitions, and new product launches in the field of breast imaging, due to the presence of key market players in the region are boosting the market region. For instance, in December 2020, Hologic, Inc, received United States Food and Drug Administration (USFDA) clearance and commercial availability for the Company’s Genius AI Detection technology. It is a new deep learning-based software that can assist radiologists to detect probable tumors in tomosynthesis images of the breast. The software provides crucial parameters during image acquisition to assist radiologists in categorizing and prioritizing cases based on their complexity and predicted read time to improve workflow and speed up patient care. Similarly, in May 2022, iCAD, Inc. promulgated its new research supporting ProFound AI for Digital Breast Tomosynthesis (DBT), company will be showcasing its complete suite of deep-learning breast cancer detection, density assessment, and risk evaluation solutions at the Society of Breast Imaging (SBI/ACR) Breast Imaging Symposium.

Thus, due to the aforesaid mentioned reasons, the market is expected to show significant growth over the forecast period in the region.

Competitive Landscape

The digital breast tomosynthesis equipment market is moderately consolidated and consists of a few major players. Some of the prominent players operating in the digital breast tomosynthesis (DBT) Equipment market are Hologic, Inc, GE Healthcare, Fujifilm Holdings Corporation, Siemens Healthineers, General Medical Merate SpA (IMS GIOTTO SPA), Analogic Corporation, Trivitron Healthcare, Metaltronica Spa, Varex Imaging Corporation, PerkinElmer Inc. (Dexela Ltd.), and Planmed OY.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.